Page last updated: 2024-08-22

trimetazidine and Angiogenesis, Pathologic

trimetazidine has been researched along with Angiogenesis, Pathologic in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Hang, WJ; Peng, YZ; Shen, L; Shu, HY; Wang, DW; Zhang, M; Zhou, N1
Fu, M; Hao, K; Li, S; Liu, Y; Yang, Q; Yang, X; Zhou, Z1

Other Studies

2 other study(ies) available for trimetazidine and Angiogenesis, Pathologic

ArticleYear
Trimetazidine enhances myocardial angiogenesis in pressure overload-induced cardiac hypertrophy mice through directly activating Akt and promoting the binding of HSF1 to VEGF-A promoter.
    Acta pharmacologica Sinica, 2022, Volume: 43, Issue:10

    Topics: Angiogenesis Inducing Agents; Animals; Cardiomegaly; Heat Shock Transcription Factors; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Myocardium; Myocytes, Cardiac; Neovascularization, Pathologic; Norepinephrine; Promoter Regions, Genetic; Proto-Oncogene Proteins c-akt; Transcription Factors; Trimetazidine; Vascular Endothelial Growth Factor A

2022
Trimetazidine mitigates high glucose-induced retinal endothelial dysfunction by inhibiting PI3K/Akt/mTOR pathway-mediated autophagy.
    Bioengineered, 2022, Volume: 13, Issue:3

    Topics: Autophagy; Cell Proliferation; Endothelial Cells; Glucose; Humans; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Trimetazidine

2022